CL2013000085A1 - Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras. - Google Patents

Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.

Info

Publication number
CL2013000085A1
CL2013000085A1 CL2013000085A CL2013000085A CL2013000085A1 CL 2013000085 A1 CL2013000085 A1 CL 2013000085A1 CL 2013000085 A CL2013000085 A CL 2013000085A CL 2013000085 A CL2013000085 A CL 2013000085A CL 2013000085 A1 CL2013000085 A1 CL 2013000085A1
Authority
CL
Chile
Prior art keywords
chlorophenoxy
methylpropyl
pyrrolidine
obesity
pain
Prior art date
Application number
CL2013000085A
Other languages
English (en)
Inventor
Daisuke Roland Saito
Miroslav Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44510052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CL2013000085A1 publication Critical patent/CL2013000085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y ácido clorhídrico en una relación molar 1:1; composición farmacéutica; proceso de preparación; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.
CL2013000085A 2010-07-09 2013-01-09 Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras. CL2013000085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36277310P 2010-07-09 2010-07-09

Publications (1)

Publication Number Publication Date
CL2013000085A1 true CL2013000085A1 (es) 2013-03-15

Family

ID=44510052

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000085A CL2013000085A1 (es) 2010-07-09 2013-01-09 Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.

Country Status (20)

Country Link
US (4) US8163794B2 (es)
EP (1) EP2590941A1 (es)
JP (2) JP5823512B2 (es)
KR (1) KR20130041916A (es)
CN (1) CN103038211B (es)
AR (1) AR083512A1 (es)
AU (1) AU2011276416B2 (es)
BR (1) BR112013000602A2 (es)
CA (1) CA2803090A1 (es)
CL (1) CL2013000085A1 (es)
CO (1) CO6680604A2 (es)
IL (1) IL223584A0 (es)
MX (1) MX2013000334A (es)
NZ (1) NZ605490A (es)
PH (1) PH12013500051A1 (es)
RU (1) RU2013105479A (es)
SG (1) SG186789A1 (es)
TW (1) TW201206882A (es)
WO (1) WO2012006205A1 (es)
ZA (1) ZA201300154B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
WO2012006205A1 (en) * 2010-07-09 2012-01-12 Theravance, Inc. Crystalline form of a 3-phenoxymethylpyrrolidine compound
US11013340B2 (en) 2018-05-23 2021-05-25 L&P Property Management Company Pocketed spring assembly having dimensionally stabilizing substrate
US12369722B2 (en) 2018-05-23 2025-07-29 L&P Property Management Company Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
EP1184372B1 (en) * 2000-08-31 2006-04-26 Pfizer Limited Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs)
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
JP2010501542A (ja) * 2006-08-23 2010-01-21 ファイザー・プロダクツ・インク ピペリジン誘導体
CA2687721A1 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TWI438190B (zh) * 2008-07-24 2014-05-21 Theravance Inc ３－（苯氧基苯基甲基）吡咯啶化合物
JP2012524098A (ja) * 2009-04-15 2012-10-11 セラヴァンス， インコーポレーテッド ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
WO2012006205A1 (en) * 2010-07-09 2012-01-12 Theravance, Inc. Crystalline form of a 3-phenoxymethylpyrrolidine compound

Also Published As

Publication number Publication date
BR112013000602A2 (pt) 2016-07-05
US20150080450A1 (en) 2015-03-19
JP2013532170A (ja) 2013-08-15
US8163794B2 (en) 2012-04-24
SG186789A1 (en) 2013-02-28
JP2015120752A (ja) 2015-07-02
JP5823512B2 (ja) 2015-11-25
PH12013500051A1 (en) 2017-10-25
CA2803090A1 (en) 2012-01-12
US20120010265A1 (en) 2012-01-12
CN103038211A (zh) 2013-04-10
AR083512A1 (es) 2013-03-06
IL223584A0 (en) 2013-03-05
RU2013105479A (ru) 2014-08-20
MX2013000334A (es) 2013-02-26
AU2011276416A1 (en) 2013-02-14
KR20130041916A (ko) 2013-04-25
AU2011276416B2 (en) 2015-04-02
CO6680604A2 (es) 2013-05-31
US9120746B2 (en) 2015-09-01
EP2590941A1 (en) 2013-05-15
US20120178790A1 (en) 2012-07-12
US20140018407A1 (en) 2014-01-16
NZ605490A (en) 2014-10-31
CN103038211B (zh) 2015-04-15
TW201206882A (en) 2012-02-16
WO2012006205A1 (en) 2012-01-12
US8791151B2 (en) 2014-07-29
US8383669B2 (en) 2013-02-26
ZA201300154B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
MX341072B (es) Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
MX382516B (es) Composiciones y metodos para absorcion transmucosa.
MX363007B (es) Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
MX392150B (es) Moduladores de receptores canabinoides.
PH12014501991A1 (en) Phenicol antibacterials
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CL2013000085A1 (es) Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
CL2012002259A1 (es) Forma cristalina de 4-{(1s,2s)-2-[84-ciclobutilpiperazin-1-il-carbonil]ciclopropil}benzamida; composicion farmacéutica; y su uso para tratar enfermedades tales como esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastornos por deficit de atencion con hiperactividad, dolor, entre otras.
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
MX2013006031A (es) Formulacion liposomal de dalcetrapib.